Influence of aspirin and statin use on gene expression in monocytes and platelets in vivo

Influence of aspirin and statin use on gene expression in monocytes and platelets in vivo - Influence of aspirin and statin use on gene expression

Status

Active, not recruiting

Phases

Unknown

Study type

Interventional

Source

NL-OMON

Registry ID

NL-OMON31926

Enrollment

Registered

2008-04-11

Start date

2008-04-01

Completion date

Unknown

Last updated

2024-05-13

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

coronary artery disease coronary atherosclerosis

Interventions

Statin and aspirin administration, venapuncture.

Eligibility

Age

18 Years to 99 Years

Inclusion criteria

Inclusion criteria: Previously participated as healthy control in MEC 06/144 and 1. Healthy 2. Caucasoid 3. No history of CVD 4. No family history positive for CVD

Exclusion criteria

Exclusion criteria: 1. Allergy for Aspirin or Simvastatin 2. Liverfunction disorders 3. CPK above three times upper normal limit. 4. Renal impairment 5. For ascal use: a. Gastric i. pain or complaints with former use ii. bleeding or perforations b. Ulcers in stomach, esophagus or bowels. c. Serious heart failure d. Hypotrombinemia e. History of cerebrovascularbleeding f. Use of other anticoagulation 6. For statin use: Use of other medication which inhibit CYP345 ie. Ketoconazol, itraconazol, HIV-protease inhibitors, erytromycine, claritromycine, telitromycine, nefazodon 7. Consumption of excessive amounts of alcohol defined as 21 units/week 8. Hypothyreodism 9. Familiar muscle disorders

Design outcomes

Primary

Measure	Time frame
gene expression profile in monocytes and platelets as result of statin and aspirin	—

Secondary

Measure	Time frame
none	—

Countries

Netherlands

Outcome results

None listed

Source: NL-OMON (via WHO ICTRP)